Update

$Repare Therapeutics (RPTX.US)$ Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
5 MINUTES AGO, 7:05 AM EDT
VIA BUSINESSWIRE

免責聲明：社區由Moomoo Technologies Inc.提供，僅用於教育目的。更多信息